Polycystic ovary syndrome (PCOS) is a common endocrine condition affecting women of reproductive age worldwide, with estimates of about 8–13%. How often it’s reported depends on diagnostic criteria, which also helps explain why prevalence can vary—from 0.56% to 26% in adolescents—and why many people are never identified. On this page, we break down the Rotterdam and NIH definitions, what the lab and ultrasound findings mean, and how risk factors relate to metabolic and reproductive features.
Key Takeaways
- Rotterdam criteria require 2 of 3: oligo/anovulation (present in 75%), hyperandrogenism (70%), polycystic ovaries (75%)
- NIH 1990 criteria: hyperandrogenism + oligo/anovulation, excludes ovarian morphology, used in 50% studies
- Androgen excess measured by free testosterone >99th percentile in 70%
- Approximately 8-13% of women of reproductive age (between 15 and 44 years old) are affected by polycystic ovary syndrome (PCOS) worldwide
- In the United States, an estimated 5 million women of reproductive age have PCOS, representing about 1 in 10 women
- Up to 70% of women with PCOS remain undiagnosed globally
- Family history of PCOS increases risk 2.5-7 fold
- Obesity triples PCOS risk, BMI >30 associated with OR 3.5
- Genetic heritability estimated at 70-80% from twin studies
- Hirsutism is present in 60-70% of women with PCOS
- Oligo- or anovulation occurs in 70-80% of PCOS cases
- Hyperandrogenemia is detected in 70-80% of PCOS patients via lab tests
- Lifestyle intervention leads to 5-10% weight loss in 55% PCOS women at 6 months
- Metformin reduces insulin resistance by 20-30% in 70% patients
- Combined oral contraceptives improve hirsutism in 60-70% after 6-12 months
PCOS affects 8 to 13% of women, yet up to 70% remain undiagnosed despite common hormonal and ovulation signs.
Related reading
01 · Category
Diagnosis/criteria24 stats
01
Rotterdam criteria require 2 of 3: oligo/anovulation (present in 75%), hyperandrogenism (70%), polycystic ovaries (75%)
02
NIH 1990 criteria: hyperandrogenism + oligo/anovulation, excludes ovarian morphology, used in 50% studies
03
Androgen excess measured by free testosterone >99th percentile in 70%
04
Pelvic ultrasound shows ≥12 follicles 2-9mm or ovarian volume >10mL in 80%
05
AMH levels >4.7 ng/mL diagnostic surrogate for polycystic ovaries, sensitivity 92%
06
Ferriman-Gallwey score ≥8 indicates hirsutism in 65% Caucasian women
07
Fasting glucose/insulin for HOMA-IR >2.5 indicates IR in 70%
08
Transvaginal ultrasound preferred over abdominal, detects 85% polycystic morphology
09
SHBG <30 nmol/L supports hyperandrogenemia diagnosis
10
17-hydroxyprogesterone to rule out late-onset CAH, >2 ng/mL abnormal
11
Prolactin exclusion if >25 ng/mL, thyroid TSH >4.5 mIU/L
12
AE-PCOS Society recommends against routine ovarian ultrasound in adults
13
Oligomenorrhea defined as <8 cycles/year or cycle >35 days
14
Hyperandrogenism clinical in 75%, biochemical in 50% overlap
15
IMT for adolescent diagnosis: irregular menses + hirsutism/acne/AND elevation
16
MRI for ovarian volume in obese patients, accuracy 90%
17
DHEAS >upper limit rules in adrenal source 10-20%
18
OGTT preferred for glucose intolerance screening, detects 30% impaired
19
FAI (free androgen index) >4.5 diagnostic in 68%
20
Androstenedione elevated >3.5 ng/mL in 40% PCOS
21
Menstrual diary + hormone levels confirm oligoanovulation 95%
22
Rule out hyperthecosis if testosterone >150 ng/dL
23
Lipid profile abnormal in 70%, triglycerides >150 mg/dL
24
HbA1c >5.7% screens prediabetes in 40% at diagnosis
Interpretation
Diagnosis/criteria Interpretation
Across commonly used PCOS diagnostic frameworks, the Rotterdam criteria appear most inclusive because 75% of cases meet oligo or anovulation and 75% show polycystic ovarian morphology, so studies using these thresholds capture more than the NIH 1990 approach that relies on hyperandrogenism plus oligo or anovulation and is used in only 50% of studies.
02 · Category
Prevalence/epidemiology30 stats
01
Approximately 8-13% of women of reproductive age (between 15 and 44 years old) are affected by polycystic ovary syndrome (PCOS) worldwide
02
In the United States, an estimated 5 million women of reproductive age have PCOS, representing about 1 in 10 women
03
Up to 70% of women with PCOS remain undiagnosed globally
04
Prevalence of PCOS among adolescent girls ranges from 0.56% to 26% depending on diagnostic criteria used
05
In South Asian women, PCOS prevalence is 5.4% compared to 1.1% in Chinese women, showing ethnic variations
06
A meta-analysis of 35 studies found PCOS prevalence of 12% using Rotterdam criteria in adult women
07
In Iran, PCOS affects 6.2% of reproductive-aged women based on national surveys
08
Among Indigenous Australian women, PCOS prevalence reaches 20-30%
09
PCOS prevalence increases with obesity, with 20-40% in obese women vs 5-10% in lean women
10
In Spain, 6.5% of women aged 18-45 have PCOS per community-based study
11
Global systematic review estimates 116 million women affected by PCOS
12
In the UK, PCOS prevalence is 9.4% among women attending general practices
13
Among Latina women in the US, PCOS prevalence is 13%, higher than non-Hispanic whites at 6%
14
In adolescents with type 2 diabetes, PCOS prevalence is 25-30%
15
Rotterdam criteria yield 11.2% prevalence vs 2.2% with NIH criteria in community samples
16
In India, PCOS affects 22.5% of adolescent girls in urban areas
17
PCOS prevalence in postmenopausal women is 17% based on ovarian morphology
18
Among women with infertility, 70-80% of anovulatory cases are due to PCOS
19
In Turkey, 20% of women in reproductive age have PCOS per hospital data
20
African American women have 1.5-fold higher PCOS risk than white women
21
In Greece, PCOS prevalence is 6.8% using Rotterdam criteria
22
Community-based prevalence in Denmark is 10%
23
In Brazil, 8.6% of women aged 12-49 have PCOS
24
PCOS affects 1 in 15 women globally per endocrine society estimates
25
In Italy, adolescent PCOS prevalence is 3.7%
26
Among PCOS sisters, familial aggregation shows 24-35% risk
27
In Japan, PCOS prevalence is 5.1% per national survey
28
US military women have 11.2% PCOS prevalence
29
In Egypt, 5.3% prevalence among university students
30
Rotterdam criteria applied to 15 countries show mean 9.8% prevalence
Interpretation
Prevalence/epidemiology Interpretation
Worldwide estimates suggest PCOS affects about 8 to 13% of women of reproductive age, yet up to 70% remain undiagnosed, underscoring a major prevalence burden that is often missed despite clear epidemiology.
03 · Category
Risk Factors/causes26 stats
01
Family history of PCOS increases risk 2.5-7 fold
02
Obesity triples PCOS risk, BMI >30 associated with OR 3.5
03
Genetic heritability estimated at 70-80% from twin studies
04
Type 2 diabetes risk 7-fold higher in PCOS women
05
Metabolic syndrome in 33-47% PCOS vs 6% controls
06
Low vitamin D levels (<20 ng/mL) in 67-85% PCOS patients
07
Gestational diabetes risk 2-3 times higher in PCOS pregnancies
08
Dyslipidemia with high LDL in 70% PCOS women
09
Childhood obesity increases adult PCOS risk by 2.5-fold
10
South Asian ethnicity OR 1.5-2 for PCOS
11
Insulin resistance prevalence 65% independent of obesity
12
Androgen excess from ovarian/adrenal sources in 80%
13
Environmental toxins like BPA associated with 2-fold risk increase
14
Maternal smoking during pregnancy raises PCOS risk OR 1.8
15
High glycemic diet increases risk by promoting insulin spikes, OR 2.1
16
Sedentary lifestyle OR 1.7 for PCOS development
17
Prenatal testosterone exposure linked to PCOS phenotype in animal models
18
Hypothyroidism comorbidity increases PCOS risk 2-fold
19
Chronic inflammation markers elevated in 50-70%
20
Gut dysbiosis with low Akkermansia in 60% PCOS microbiomes
21
Sleep disturbance OR 2.4 for PCOS symptom severity
22
Early menarche (<12 years) risk factor OR 1.6
23
Stress/cortisol dysregulation contributes to 30% cases
24
Antibiotic use in childhood alters microbiome, OR 1.4
25
FTO gene variants increase obesity-related PCOS risk 1.5-fold
26
Shift work disrupts circadian rhythm, OR 1.9 for PCOS
Interpretation
Risk Factors/causes Interpretation
PCOS risk is strongly shaped by risk factors and underlying biology, with obesity tripling the odds and genetic heritability estimated at 70 to 80 percent while metabolic complications show up far more often, including metabolic syndrome in 33 to 47 percent of cases versus 6 percent in controls.
More related reading
04 · Category
Symptoms/clinical Features29 stats
01
Hirsutism is present in 60-70% of women with PCOS
02
Oligo- or anovulation occurs in 70-80% of PCOS cases
03
Hyperandrogenemia is detected in 70-80% of PCOS patients via lab tests
04
Acne affects 15-40% of women with PCOS, often severe
05
Irregular menstrual cycles reported by 65-80% of diagnosed PCOS women
06
Alopecia (female pattern hair loss) in 4-22% of PCOS patients
07
Insulin resistance present in 50-80% of lean PCOS women and 80-95% of obese
08
Polycystic ovarian morphology on ultrasound in 70-80% under Rotterdam criteria
09
Obesity prevalence in PCOS is 40-80%
10
Fatigue reported by 40% of PCOS women in quality-of-life studies
11
Depression rates 3-4 times higher in PCOS, affecting 35-40%
12
Anxiety disorders in 42-57% of PCOS patients vs 20% controls
13
Sleep apnea risk 5-10 times higher, present in 30-50% obese PCOS
14
Non-alcoholic fatty liver disease in 30-40% of PCOS women
15
Acanthosis nigricans skin tag in 20-30% due to hyperinsulinemia
16
Infertility due to anovulation in 70-75% of PCOS infertility cases
17
Skin tags prevalence 28% in PCOS vs 7% controls
18
Chronic pelvic pain in 40% of PCOS women
19
Libido decrease in 47% of PCOS patients per surveys
20
Eating disorders 3-fold higher, bulimia in 17% PCOS women
21
Headaches/migraines in 30% PCOS vs 12% controls
22
Breast pain/cysts in 25% of PCOS cases
23
Weight gain difficulty reported by 80% despite efforts
24
Hot flashes early onset in 20% premenopausal PCOS
25
Joint pain/arthritis symptoms in 25-30%
26
Dry skin/itching in 15-20% linked to metabolic issues
27
Memory/concentration issues in 35% per cognitive studies
28
Gastrointestinal bloating in 50% PCOS women
29
Endometrial hyperplasia risk with amenorrhea in 30%
Interpretation
Symptoms/clinical Features Interpretation
Across the symptoms and clinical features of PCOS, irregular menstrual cycles and ovulation problems dominate the picture, with 65 to 80% experiencing irregular cycles and 70 to 80% having oligo or anovulation.
05 · Category
Treatment/management27 stats
01
Lifestyle intervention leads to 5-10% weight loss in 55% PCOS women at 6 months
02
Metformin reduces insulin resistance by 20-30% in 70% patients
03
Combined oral contraceptives improve hirsutism in 60-70% after 6-12 months
04
Clomiphene citrate ovulation induction success 60-80% first cycle
05
Letrozole superior to clomiphene, 27% vs 19% live birth rate in PCOS
06
Bariatric surgery achieves 50% remission of PCOS symptoms in obese
07
Spironolactone reduces hirsutism score by 30-40% in 80% women
08
Inositol (myo-inositol 2g/day) restores ovulation in 70% lean PCOS
09
Exercise 150 min/week + diet reduces BMI by 7% in 65%
10
GLP-1 agonists like liraglutide weight loss 5-8kg in 50% at 26 weeks
11
Laser hair removal 50-70% reduction after 6 sessions
12
Pioglitazone improves IR but weight gain 2-3kg in 40%
13
IVF success rates similar to non-PCOS but higher OHSS risk 20%
14
Vitamin D supplementation normalizes levels in 85%, improves fertility 30%
15
Low GI diet ovulation restoration 50% vs 20% high GI
16
Metformin + CC increases ovulation 88% vs 76% CC alone
17
Cognitive behavioral therapy reduces depression scores 40% in PCOS
18
Flutamide antiandrogen reduces acne 70% but hepatotoxic
19
Progestin therapy prevents endometrial hyperplasia 95% efficacy
20
Omega-3 reduces inflammation markers 25% in 60%
21
CPAP for sleep apnea improves insulin sensitivity 30%
22
Spearmint tea twice daily reduces free testosterone 30% in 8 weeks
23
Weight loss >10% normalizes menses in 90% obese PCOS
24
Eflornithine cream reduces facial hair 30% in 6 months
25
Acupuncture ovulation rate 45% vs 20% sham
26
Statins reduce LDL 20-30% improve ovarian function 25%
27
Probiotics improve gut health, ovulation +15% in trials
Interpretation
Treatment/management Interpretation
In PCOS management, the biggest gains come when treatments are matched to the problem, with lifestyle changes producing 5 to 10 percent weight loss in 55 percent of women at 6 months and ovulation focused options like letrozole reaching higher live birth rates of 27 percent versus 19 percent with clomiphene.
report visual · Breakdown
PCOS Diagnosis Criteria: Rotterdam vs NIH
The two most common diagnostic frameworks differ mainly in whether ovarian morphology is required.
70%
Androgen excess measured by free testosterone >99th percentile in 70%
30%
OGTT preferred for glucose intolerance screening, detects 30% impaired
report visual · Key figures
PCOS prevalence: global vs country estimates
PCOS is common worldwide, with global estimates and country-specific prevalence showing variability across populations and diagnostic approaches.
-13%
Approximately 8-13% of women of reproductive age (between 15 and 44 years old) are affected by polycystic ovary syndrome
9.8%
Rotterdam criteria applied to 15 countries show mean 9.8% prevalence
9.4%
In the UK, PCOS prevalence is 9.4% among women attending general practices
6.5%
In Spain, 6.5% of women aged 18-45 have PCOS per community-based study
6.2%
In Iran, PCOS affects 6.2% of reproductive-aged women based on national surveys
report visual · Key figures
Key PCOS Risk Factors: Metabolic, hormonal, and lifestyle
PCOS risk is strongly linked to family/genetic predisposition, androgen excess, and insulin-resistance–related metabolic factors, alongside lifestyle influences.
2.5
Family history of PCOS increases risk 2.5-7 fold
80%
Androgen excess from ovarian/adrenal sources in 80%
65%
Insulin resistance prevalence 65% independent of obesity
2
Type 2 diabetes risk 7-fold higher in PCOS women
-47%
Metabolic syndrome in 33-47% PCOS vs 6% controls
1.7
Sedentary lifestyle OR 1.7 for PCOS development
report visual · Comparison
Common clinical features of PCOS (prevalence)
Most PCOS clinical features are common, with irregular cycles and lab-detected hyperandrogenemia among the most prevalent.
Irregular menstrual cycles reported by 65-80% of diagnosed PCOS women-80%
Hyperandrogenemia is detected in 70-80% of PCOS patients via lab tests
-80%
Oligo- or anovulation occurs in 70-80% of PCOS cases
-80%
Hirsutism is present in 60-70% of women with PCOS
-70%
report visual · Breakdown
Treatment/management options for PCOS: fertility & metabolic targets
Common interventions can improve ovulation and metabolic outcomes—though effects vary by treatment and endpoint.
50%
Bariatric surgery achieves 50% remission of PCOS symptoms in obese
50%
GLP-1 agonists like liraglutide weight loss 5-8kg in 50% at 26 weeks
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Megan Gallagher. (2026, February 13). Pcos Statistics. Gitnux. https://gitnux.org/pcos-statistics
MLA
Megan Gallagher. "Pcos Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pcos-statistics.
Chicago
Megan Gallagher. 2026. "Pcos Statistics." Gitnux. https://gitnux.org/pcos-statistics.
Sources & references
17 datasets cited across this report · attribution is report-level